Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07604233 | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | not yet recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients(VABu) |
| not yet recruiting |
| N/A |
| 42 |
| The First Affiliated Hospital of Soochow UniversityOTHER |
| 1 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT07774377 | Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma(CHI-HSCT) | not yet recruiting | Phase 3 | 132 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07774390 | Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL(I+V-LT) | recruiting | — | 323 | European Research Initiative on CLLNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00923013 | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT03719105 | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | recruiting | Early Phase 1 | 40 | New York Medical CollegeOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03906292 | Frontline Asciminib Combination in Chronic Phase CML(CMLXI) | active not recruiting | Phase 2 | 125 | University of JenaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05701215 | Venetoclax After TKI to Target Persisting Stem Cells in CML(VARIANT) | completed | Phase 2 | 10 | Thomas Ernst, PD Dr. med.OTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06656494 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | recruiting | Phase 1 | 266 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 3 | Aug 18, 2026 | clinicaltrials |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia(PROSPERA) | recruiting | Phase 2 | 66 | TheradexINDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT07153796 | A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07549464 | Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies | recruiting | Phase 1 | 48 | Sawa Ito, MDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)(Soursop) | recruiting | Early Phase 1 | 20 | Roger StrairOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06528301 | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | recruiting | Phase 1 | 106 | Umoja BiopharmaINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07227584 | ALL Backbone in AYAs | recruiting | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | recruiting | Phase 1 | 50 | Stanford UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07740174 | Efficacy of Seated Exercise on Functional Capacity and Quality of Life in Patients With Leukemia During Chemotherapy Cycles | not yet recruiting | N/A | 30 | Suez UniversityOTHER | 0 | Aug 17, 2026 | clinicaltrials |
| NCT04013685 | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | active not recruiting | Phase 1 | 155 | Orca Biosystems, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04173533 | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT(AMADEUS) | completed | Phase 3 | 326 | University of BirminghamOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | active not recruiting | — | 350 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05150561 | Muscle Dysfunction in Patients With Haematological Diseases | active not recruiting | — | 216 | Rigshospitalet, DenmarkOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05428176 | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors | active not recruiting | N/A | 332 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06274788 | Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | recruiting | — | 40 | Fresenius KabiINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06296368 | DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics(DISCOVERY) | recruiting | N/A | 500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06459024 | Master Framework For Relapse or Refractory Acute Myeloid Leukemia(IMPACT STREAM) | recruiting | — | 4,000 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 6 | Aug 14, 2026 | clinicaltrials |
| NCT06713837 | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.(IMPACT-AML) | recruiting | Phase 3 | 339 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 7 | Aug 14, 2026 | clinicaltrials |
| NCT07191119 | Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia | recruiting | N/A | 40 | St. Jude Children's Research HospitalOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | recruiting | Phase 1 / Phase 2 | 29 | Chaser Therapeutics, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01728402 | Pathogenesis of Hematologic Malignancies | enrolling by invitation | — | 5,000 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT02732184 | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | completed | Phase 1 | 21 | Immedica Pharma ABINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03737955 | Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 | 36 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03911128 | A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | — | 500 | Mats HeymanOTHER | 8 | Aug 13, 2026 | clinicaltrials |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | withdrawn | Phase 1 / Phase 2 | 0 | Kevin McNerneyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06762431 | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.(VTB-CLL002) | recruiting | Phase 1 / Phase 2 | 24 | Vitebsk Regional Clinical Cancer CentreOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06771830 | Evaluation of Pediatric eCART Implementation | recruiting | N/A | 30,000 | University of Wisconsin, MadisonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07469592 | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation | recruiting | N/A | 165 | University of MiamiOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07570407 | Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation(QiNKT-HSCT) | recruiting | — | 75 | University Hospital PilsenOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07727083 | Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases(EBV-T/NK Cohor) | recruiting | — | 1,500 | Rong TaoOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07759661 | Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies(IMPACT) | not yet recruiting | — | 64 | IRCCS San RaffaeleOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | recruiting | — | 30 | Haikou Affiliated Hospital of Central South University Xiangya School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2026source: clinicaltrials